Discover how THERAtRAME SA, a spin-off from the University of Liege and WELBIO, is developing groundbreaking therapeutic solutions against cancer through innovative tRNA epitranscriptomics.

Introduction to THERAtRAME SA

In the relentless battle against cancer, cancer therapeutic innovations are crucial for developing more effective and targeted treatments. THERAtRAME SA stands at the forefront of this fight, leveraging cutting-edge science to create novel cancer therapies. As a spin-off from the University of Liege and WELBIO, THERAtRAME SA has recently secured €4.5 million in seed financing to advance its pioneering approach in the field of tRNA epitranscriptomics.

Breaking New Ground with tRNA Epitranscriptomics

Understanding tRNA Epitranscriptomics

tRNA epitranscriptomics involves the study of chemical modifications on transfer RNA (tRNA), which play a vital role in protein synthesis. THERAtRAME SA’s research has unveiled how cancer cells manipulate tRNA modifications to enhance their growth, metastasis, and resistance to existing treatments. By targeting these modifications, THERAtRAME aims to disrupt the protein synthesis machinery of cancer cells, offering a novel avenue for therapy.

AI-Driven Drug Discovery Platform

At the heart of THERAtRAME’s innovation is its proprietary artificial intelligence (AI) platform. This technology accelerates the discovery of first-in-class small molecule therapeutics by identifying unpredicted key players in cancer development. The AI-driven approach not only speeds up the drug discovery process but also increases the precision in targeting cancer-specific vulnerabilities.

Securing Strategic Funding

THERAtRAME SA’s €4.5 million seed financing underscores confidence in its unique approach. The funding consists of:

€2.5 million from the interuniversity fund QBIC3
Public institutional funds including NOSHAQ and S.R.I.W.
Equity investment from the University of Liege’s technology transfer arm, Gesval SA
Support from angel investors and a €2.0 million subsidy from the Walloon Region

This robust financial backing enables THERAtRAME to advance its research and development efforts, bringing innovative cancer therapies closer to clinical application.

Leadership and Expertise

THERAtRAME SA is led by a team of esteemed scientists and experienced industry professionals:

Dr. Pierre Close, Chief Scientific Officer, specializes in cancer signaling and the mechanisms of cancer development.
Dr. Francesca Rapino, Chief Operating Officer, focuses on cancer stem cells and cellular differentiation.
Mr. Ching Man Choi, Chief Executive Officer, brings extensive experience in biotech financing and corporate development.
Dr. Marc Zabeau, Chairman of the Board, offers over 30 years of experience in biotech ventures.

Their combined expertise drives THERAtRAME’s mission to translate fundamental discoveries into effective cancer treatments.

Strategic Collaborations and Support

THERAtRAME SA benefits from strong collaborations with the GIGA Institute at the University of Liege and WELBIO. These partnerships provide access to state-of-the-art research facilities and a network of leading scientists in biomedical sciences. Additionally, support from QBIC3, NOSHAQ, and S.R.I.W. ensures that THERAtRAME has the resources needed to thrive in the competitive biotech landscape.

Impact on the Walloon Economy

By fostering innovation in cancer therapeutic solutions, THERAtRAME SA contributes to the economic resilience of Wallonia. The company’s success not only advances medical science but also creates high-skilled jobs and stimulates the local biotech industry. Initiatives like the Walloon Entrepreneur Support Network (WESN) further bolster this impact by providing comprehensive support to entrepreneurs in the region.

Future Prospects

THERAtRAME SA is poised to make significant strides in cancer treatment through its innovative approach. With continuous advancements in cancer therapeutic innovations and sustained financial and institutional support, the company is set to deliver groundbreaking therapies that could transform cancer care.

“It is truly exciting to translate our fundamental discoveries in the field of tRNA epitranscriptomics into clinical applications that we hope will provide new therapeutic possibilities for cancer patients.”
— Pierre Close and Francesca Rapino, co-founders of THERAtRAME

Conclusion

THERAtRAME SA exemplifies the potential of combining innovative research with strategic support to achieve meaningful advancements in cancer therapy. As the company progresses, it remains dedicated to overcoming the challenges of cancer treatment and enhancing the quality of life for patients worldwide.

Discover more about how the Walloon Entrepreneur Support Network (WESN) and organizations like THERAtRAME SA are driving cancer therapeutic innovations and supporting the entrepreneurial ecosystem in Wallonia.

Join the Walloon Entrepreneur Support Network today!